TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3161422

Group type: EXPERIMENTAL
Intervention: Sufentanil (20 micrograms/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fentanyl (100 micrograms/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sufentanil (20 micrograms/kg) and Fentanyl (100 micrograms/kg)
Number of subjects: 48
Study: 29799668

Group type: EXPERIMENTAL
Intervention: numeric with an icon array
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: numeric with a set of 50 images
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: numeric with a functional spinner
Number of subjects: 648

Group type: COMPARATOR
Intervention: numeric only format
Number of subjects: 648
Study: 25085651

Group type: EXPERIMENTAL
Intervention: Auditory attention
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Visual attention
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both auditory and visual modalities
Number of subjects: 50
Study: 25872500

Group type: EXPERIMENTAL
Intervention: Sessions with a trained Physical Activity Facilitator delivering an intervention based on self‐determination theory
Number of subjects: 60

Group type: COMPARATOR
Intervention: Booklet on healthy ageing
Number of subjects: 60
Study: 24051419

Group type: EXPERIMENTAL
Intervention: Fingolimod (Gilenya)
Number of subjects: 712
Study: 21888842

Group type: EXPERIMENTAL
Intervention: Zifko method of minimally invasive osteosynthesis with intramedullary K‐wire insertion (MIO group)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Open reduction with angle‐stable osteosynthesis using a Philos plate (ORIF group)
Number of subjects: 55
Study: 19487582

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Lercanidipine
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 59

Group type: COMPARATOR
Intervention: All 4 classes of drug
Number of subjects: 59

Group type: COMPARATOR
Intervention: All drugs
Number of subjects: 59
Study: 17076365

Group type: EXPERIMENTAL
Intervention: Gastrojejunostomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stent placement
Number of subjects: 0
Study: 19785223

Group type: EXPERIMENTAL
Intervention: Veterinarians delivering education materials during routine dairy herd health visits
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Veterinarians providing client lists for mailing education materials
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group with veterinarians providing client lists but no education materials
Number of subjects: 27
Study: 11759861

Group type: COMPARATOR
Intervention: Flap surgery plus autogenous bone grafts alone (FG) (controls, n = 12)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Flap surgery plus non-resorbable barriers (FGM) (test 1, n = 20)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Flap surgery plus bioabsorbable barriers (FGRM) (test 2, n = 9)
Number of subjects: 25
Study: 9380803

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (2.5 mg/l of dialysis solution)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (5 mg/l of dialysis solution)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Isoprenaline hydrochloride (0.5 mg/l of dialysis solution)
Number of subjects: 41

Group type: COMPARATOR
Intervention: 1.5 g% glucose dialysis solution
Number of subjects: 41
Study: 7871062

Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Melatonin 20 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Melatonin 40 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Melatonin 80 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3530447

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 115

Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES)
Number of subjects: 115
Study: 30255400

Group type: COMPARATOR
Intervention: Amiodarone (AMIO) monotherapy (300 mg in 30 min + 1125 mg in 36 h iv)
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Amiodarone plus Ranolazine (AMIO + RAN) combination (500 mg po + 375 mg after 6 h and 375 mg twice daily thereafter)
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Left atrial diameter comparison
Number of subjects: 812
Study: 27496105

Group type: EXPERIMENTAL
Intervention: Levosimendan infusion (0.1 μg/kg/min for 24 hours)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Levosimendan infusion
Number of subjects: 340
Study: 24650009

Group type: EXPERIMENTAL
Intervention: Sotatercept (0.1, 0.3, or 0.5 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sotatercept
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22181973

Group type: EXPERIMENTAL
Intervention: 5 mg letrozole/day for five days combined with intrauterine insemination
Number of subjects: 136

Group type: COMPARATOR
Intervention: 100 mg clomiphene citrate/day for five days combined with intrauterine insemination
Number of subjects: 136
Study: 19781127

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention (12-week teacher-implemented program with parent seminars)
Number of subjects: 191
Study: 18853679

Group type: EXPERIMENTAL
Intervention: Clonidine (0.15 mg orally 60 minutes before surgery) and ketamine (20 mg intravenous bolus followed by intraoperative perfusion of 20 mg h(‐1))
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Clonidine and ketamine
Number of subjects: 31
Study: 16135340

Group type: EXPERIMENTAL
Intervention: Greater depressive symptoms (DS)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Worse mental health functioning (MHF)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Clinically significant worsening (10 points) of DS and MHF
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Male sex, heroin as a problem substance, and race/ethnicity
Number of subjects: 400
Study: 12566361

Group type: EXPERIMENTAL
Intervention: Elevated VEGF serum levels
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: High HGF levels
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: HGF levels
Number of subjects: 1090
Study: 10225081

Group type: EXPERIMENTAL
Intervention: General Anaesthesia (GA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spinal Anaesthesia (SA)
Number of subjects: 40
Study: 8688997

Group type: EXPERIMENTAL
Intervention: 100 mg losigamone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 300 mg losigamone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 700 mg losigamone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 500 mg losigamone for 6 days (t.i.d.)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 400 mg losigamone for 28 days
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 1,200 mg losigamone for 28 days
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 1,800 mg losigamone for 28 days
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Caffeine and antipyrine kinetics
Number of subjects: 52
Study: 2070860

Group type: EXPERIMENTAL
Intervention: Follicles yielding successfully fertilized and cleaved ova
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Follicles with mature oocyte‐corona‐cumulus complexes and unfertilized oocytes
Number of subjects: 55
Study: 6129370

Group type: EXPERIMENTAL
Intervention: hpGRF-40 (1 microgram/kg bodyweight, administered as an intravenous bolus)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: hpGRF-40
Number of subjects: 6
Study: 30908853

Group type: EXPERIMENTAL
Intervention: FHSQ pain subscale
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: FFI‐RS pain subscale
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 100‐mm VAS of pain severity while walking
Number of subjects: 88
Study: 30786861

Group type: EXPERIMENTAL
Intervention: 12-week moderate-intensity exercise program (Borg perceived rating scale 13-14), at least three times weekly; one supervised group training and two home-based sessions.
Number of subjects: 724

Group type: COMPARATOR
Intervention: Standard prenatal care (control group).
Number of subjects: 724
Study: 29042662

Group type: EXPERIMENTAL
Intervention: PegIFNα-2b
Number of subjects: 98

Group type: COMPARATOR
Intervention: Continuing NA therapy
Number of subjects: 98
Study: 27054324

Group type: EXPERIMENTAL
Intervention: Meeting physical activity guidelines of 150 moderate and vigorous minutes per week (≥ 600 MET adjusted minutes)
Number of subjects: 3414

Group type: EXPERIMENTAL
Intervention: Total minutes per week of moderate and vigorous/strenuous activity greater than 743 MET adjusted minutes
Number of subjects: 3414

Group type: COMPARATOR
Intervention: Participants who did not meet US physical activity guidelines
Number of subjects: 3414
Study: 25099775

Group type: EXPERIMENTAL
Intervention: RehaCom cognitive training
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Combination of RehaCom cognitive training and acupuncture
Number of subjects: 240

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 240
Study: 22824097

Group type: EXPERIMENTAL
Intervention: DAS‐steered treatment (DAS ≤ 2.4)
Number of subjects: 275
Study: 19615091

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (target carbohydrate content: <40% energy)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Low-fat diet (target carbohydrate content: >55% energy)
Number of subjects: 200
Study: 17916060

Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oseltamivir postexposure prophylaxis
Number of subjects: 0
Study: 15073704

Group type: COMPARATOR
Intervention: Nitric oxide (NO)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Continuous infusion of milrinone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of milrinone and NO
Number of subjects: 90
Study: 11835382

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (8g/m2)
Number of subjects: 37
Study: 9509951

Group type: EXPERIMENTAL
Intervention: Molar pregnancy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal pregnancy
Number of subjects: 20
Study: 7997415

Group type: EXPERIMENTAL
Intervention: Prednisone 2 mg/kg/day reducing to zero over 14 days (n = 12)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 21
Study: 2834942

Group type: EXPERIMENTAL
Intervention: High-fiber diet for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-fiber diet for 8 weeks
Number of subjects: 0
Study: 31239112

Group type: EXPERIMENTAL
Intervention: E2/DRSP
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: E2/NETA
Number of subjects: 120
Study: 27651218

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metformin 1.5 g daily
Number of subjects: 20
Study: 25179468

Group type: EXPERIMENTAL
Intervention: Protein-enriched bread and drinking yoghurt
Number of subjects: 47

Group type: COMPARATOR
Intervention: Normal, non-enriched products
Number of subjects: 47
Study: 23273855

Group type: EXPERIMENTAL
Intervention: Audiovisual-print decision aid
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control group (no decision aid)
Number of subjects: 255
Study: 21112400

Group type: EXPERIMENTAL
Intervention: Intact V2rf2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted deletion of V2rf2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postnatal wild-type mice
Number of subjects: 0
Study: 18325601

Group type: COMPARATOR
Intervention: Levobupivacaine 0.25% (Group L)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25% plus magnesium sulphate 2mg/kg (Group M)
Number of subjects: 75

Group type: COMPARATOR
Intervention: NaCl 0.9% (Group S)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (Group S)
Number of subjects: 75
Study: 16929430

Group type: EXPERIMENTAL
Intervention: Cementless Harris-Galante II cup (experimental group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cemented Spectron stem (control group)
Number of subjects: 52
Study: 14618047

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic conversion strategy (n = 27)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rate-control strategy (n = 23)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic conversion strategy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rate-control strategy
Number of subjects: 50
Study: 10918423

Group type: EXPERIMENTAL
Intervention: PEG-rHuMGDF (1.0, 2.5, 5.0, 7.5, or 10.0 microg/kg/day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 8967471

Group type: EXPERIMENTAL
Intervention: acipimox
Number of subjects: 34

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study: 1729559

Group type: COMPARATOR
Intervention: Topical anesthesia with EMLA cream applied on one side of the scrotum.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Topical anesthesia with EMLA cream applied on one side of the scrotum before bilateral mepivacaine infiltration.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Infiltration anesthesia with mepivacaine on the contralateral side (first trial).
Number of subjects: 42
Study: 6710300

Group type: EXPERIMENTAL
Intervention: 0.5 per cent chlorhexidine gluconate spray
Number of subjects: 737

Group type: COMPARATOR
Intervention: povidone‐iodine scrub
Number of subjects: 737
Study: 3088636

Group type: EXPERIMENTAL
Intervention: Binedaline (50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Binedaline (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine (75 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29300925

Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (0.8 mg/kg/dose)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 27454114

Group type: EXPERIMENTAL
Intervention: Physical activity program
Number of subjects: 25

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 25
Study: 24728287

Group type: EXPERIMENTAL
Intervention: Orthotopic transplantation (OT)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Heterotopic transplantation (HT)
Number of subjects: 334
Study: 24131882

Group type: EXPERIMENTAL
Intervention: Discretionary time spent with peers
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Discretionary time spent with parents
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Discretionary time social context
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Eighth graders
Number of subjects: 25
Study: 19927151

Group type: EXPERIMENTAL
Intervention: Olmesartan (20 mg day(-1))
Number of subjects: 50

Group type: COMPARATOR
Intervention: Candesartan (8 mg day(-1))
Number of subjects: 50
Study: 19055225

Group type: COMPARATOR
Intervention: Acellular dermal matrix
Number of subjects: 0

Group type: COMPARATOR
Intervention: New surgical approach with acellular dermal matrix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acellular dermal matrix alone
Number of subjects: 0
Study: 16604818

Group type: EXPERIMENTAL
Intervention: IFNbeta‐1b‐G (glucose formulation)
Number of subjects: 303

Group type: COMPARATOR
Intervention: IFNbeta‐1b‐M (refrigeration-free formulation)
Number of subjects: 303
Study: 14705469

Group type: EXPERIMENTAL
Intervention: Coping instruction
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Coping instruction (coping alone or coping plus information)
Number of subjects: 66

Group type: COMPARATOR
Intervention: No coping instruction (control group)
Number of subjects: 66
Study: 10663062

Group type: EXPERIMENTAL
Intervention: Argon-Plasma-Coagulation tonsillectomy (TE-APC)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Traditional blunt dissection tonsillectomy (TE-trad)
Number of subjects: 133
Study: 8851595

Group type: COMPARATOR
Intervention: Conventional dosing (CD) vancomycin therapy (1 g every 12 h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous-infusion (CI) vancomycin therapy (500 mg loading dose followed by 2 g infused over 24 h)
Number of subjects: 10
Study: 1496949

Group type: EXPERIMENTAL
Intervention: Somatotropin recombinant DNA (24 IU/m2 of body surface area) subcutaneously administered in six injections per week for 2 years
Number of subjects: 52

Group type: COMPARATOR
Intervention: Somatotropin recombinant DNA (24 IU/m2 of body surface area) subcutaneously administered in three injections per week for 2 years
Number of subjects: 52
Study: 6149737

Group type: COMPARATOR
Intervention: Intravenous (IV) benztropine mesylate (2 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oral benztropine mesylate (2 mg three times a day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Neuroleptic withdrawal (four weeks of dose tapering and six weeks of placebo treatment)
Number of subjects: 36
Study: 29927751

Group type: EXPERIMENTAL
Intervention: Cognitive-motor exercise program
Number of subjects: 28

Group type: COMPARATOR
Intervention: Monitoring (control group)
Number of subjects: 28
Study: 30403937

Group type: EXPERIMENTAL
Intervention: Three-drug regimen (ivermectin + diethylcarbamazine + albendazole)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Two-drug regimen (diethylcarbamazine + albendazole) - single dose
Number of subjects: 182

Group type: COMPARATOR
Intervention: Two-drug regimen (diethylcarbamazine + albendazole) - administered once a year for 3 years
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Three-drug regimen
Number of subjects: 182
Study: 26718094

Group type: EXPERIMENTAL
Intervention: Group Cognitive-Behavioral Treatment (GCBT)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Group Supportive Counseling Approach (GPCT)
Number of subjects: 196
Study: 25323538

Group type: EXPERIMENTAL
Intervention: Sunflower seed oil (SSO) applied daily during the first 10 postnatal days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (C) with no intervention
Number of subjects: 22
Study: 22984233

Group type: EXPERIMENTAL
Intervention: Osteopathic manual treatment (OMT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham OMT
Number of subjects: 70
Study: 20733134

Group type: EXPERIMENTAL
Intervention: Oral midostaurin at 50 or 100 mg twice daily
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Oral midostaurin at 100 mg twice daily
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Oral midostaurin at 50 mg twice daily
Number of subjects: 95
Study: 19050548

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15797173

Group type: EXPERIMENTAL
Intervention: Standard instructions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Instructions to simulate pain-related memory deficit
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cold-induced pain
Number of subjects: 60
Study: 11753159

Group type: EXPERIMENTAL
Intervention: Erythromycin 10 mg/kg, 8 hourly for 7 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9848502

Group type: EXPERIMENTAL
Intervention: Isolated soy protein containing 1.39 mg isoflavones/g protein (ISP56)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Isolated soy protein containing 2.25 mg isoflavones/g protein (ISP90)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Casein and nonfat dry milk (CNFDM)
Number of subjects: 66
Study: 8019165

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of oxybutynin
Number of subjects: 36
Study: 2754021

Group type: EXPERIMENTAL
Intervention: Felodipine treatment 10 mg b.i.d. for 8 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 20121

Group type: EXPERIMENTAL
Intervention: Air injection technique
Number of subjects: 11
Study: 31129587

Group type: EXPERIMENTAL
Intervention: S100B biomonitoring group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional management control group
Number of subjects: 0
Study: 29525602

Group type: EXPERIMENTAL
Intervention: 2 mg aflibercept
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: 1.25 mg bevacizumab
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 436

Group type: COMPARATOR
Intervention: aflibercept
Number of subjects: 436

Group type: COMPARATOR
Intervention: bevacizumab
Number of subjects: 436
Study: 26404015

Group type: EXPERIMENTAL
Intervention: Stress myocardial perfusion single photon emission computed tomography (SPECT)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: High end-systolic volume (ESV) and high summed stress score (SSS)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Low estimated glomerular filtration rate (eGFR) and high summed difference score (SDS)
Number of subjects: 299
Study: 25173954

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (1 mA, 20 min)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 28
Study: 22169831

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (3 J) and exercises
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo laser and exercises
Number of subjects: 40
Study: 19605849

Group type: EXPERIMENTAL
Intervention: Fludarabine (25 mg/m² for 5 days intravenously, every 28 days, for 6 courses)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Chlorambucil (0.4 mg/kg body weight with an increase to 0.8 mg/kg, every 15 days, for 12 months)
Number of subjects: 193
Study: 17261329

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated OSA
Number of subjects: 0
Study: 14872250

Group type: EXPERIMENTAL
Intervention: 125 W exercise intensity
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 150 W exercise intensity
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 175 W exercise intensity
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 300 W exercise intensity
Number of subjects: 5
Study: 11669361

Group type: EXPERIMENTAL
Intervention: Pharmacy-based cholesterol management program
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study: 8980759

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg orally every 12 h for 45 days + Gentamicin 240 mg intramuscularly once daily for 7 days
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Doxycycline at the same dosage for 30 days + Gentamicin 240 mg intramuscularly once daily for 7 days
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both cohorts (Doxycycline and Gentamicin)
Number of subjects: 52